More about

Cholesterol

News
November 16, 2019
4 min read
Save

Twice-yearly inclisiran cuts LDL in ASCVD patients

Twice-yearly inclisiran cuts LDL in ASCVD patients

PHILADELPHIA — New data on inclisiran, an investigational cholesterol-lowering therapy in the small-interfering RNA class, demonstrate sustained LDL reductions with twice-yearly dosing in high-risk patients with atherosclerotic CVD.

News
October 26, 2019
2 min watch
Save

VIDEO: Pediatric cholesterol screening faces barriers to adoption

VIDEO: Pediatric cholesterol screening faces barriers to adoption

ATLANTA — In this video exclusive, Amy L. Peterson, MD, director of pediatric preventive cardiology and associate professor of pediatrics in the division of pediatric cardiology at the University of Wisconsin School of Medicine and Public Health in Madison, discusses her presentation at the FH Foundation’s FH Global Summit, which focused on her team’s research on cholesterol screening, especially in children to diagnose conditions like FH.

News
October 21, 2019
3 min read
Save

Underuse of cholesterol-lowering medications creates ‘missed opportunities’

Underuse of cholesterol-lowering medications creates ‘missed opportunities’

ATLANTA — Despite the improvements that have been made in cholesterol reduction, more efforts are needed to improve usage rates of cholesterol-lowering medications in patients, including those with familial hypercholesterolemia, according to a presentation at the FH Foundation’s FH Global Summit.

News
September 23, 2019
3 min read
Save

Tocilizumab increases HDL, LDL cholesterol, triglycerides compared with etanercept in RA

Tocilizumab increases HDL, LDL cholesterol, triglycerides compared with etanercept in RA

Patients with rheumatoid arthritis who received tocilizumab demonstrated 11.1% higher serum LDL cholesterol, 5.7% higher HDL cholesterol and 13.6% higher triglyceride levels than those treated with etanercept, according to data published in Arthritis & Rheumatology.

News
September 05, 2019
2 min read
Save

Fasting not required for metabolic syndrome assessment

Fasting not required for metabolic syndrome assessment

Metabolic syndrome severity may influence the risk for coronary heart disease and diabetes both when it is evaluated in a fasting state and a nonfasting state, according to findings published in Nutrition, Metabolism and Cardiovascular Diseases.

News
August 26, 2019
2 min read
Save

Low, variable HDL cholesterol level creates ‘additive effect’ for diabetes risk

Low, variable HDL cholesterol level creates ‘additive effect’ for diabetes risk

Korean adults with a variable and overall lower HDL cholesterol level are significantly more likely to develop type 2 diabetes over 5 years when compared with adults with a higher HDL cholesterol level with less fluctuation, according to a large database analysis published in The Journal of Clinical Endocrinology & Metabolism.

News
August 22, 2019
3 min read
Save

Patients with atherosclerotic CVD face ‘remarkable treatment gap’

Among a cohort of more than a quarter million patients with atherosclerotic CVD in Canada, only about two-thirds were prescribed lipid-lowering therapy and of those, more than a third did not reach recommended LDL cholesterol levels, according to findings recently published in the Canadian Journal of Cardiology.

News
August 08, 2019
3 min read
Save

Optimal CV health at midlife reduces dementia risk

Patients aged 50 years who adhered to recommendations from the American Heart Association’s Life’s Simple 7 metric for CV health had a lower risk for dementia later in life, according to a study published in The BMJ.

News
August 08, 2019
1 min read
Save

GOULD

GOULD

Researchers analyzed cholesterol treatment patterns in patients with atherosclerotic CVD.

Learn the Heart

Part of the Healio Network

Statin Topic Review

HMG-CoA reductase inhibitors, commonly referred to as statins, are the cornerstone of pharmacologic reduction of elevated low-density lipoprotein cholesterol.

View more